

AMENDMENTS**In the Claims****Canceled Claims**

Claims 33-45 are not designated as being canceled. These claims were the subject of an election/restriction requirement and are now pending in a divisional applications. Therefore, Applicant are not canceling these claims to evidence a decision to dedicate the claims to the public, but because these claims are already the subject of a divisional application cancellation merely facilitates amendment entry.

Claim Status

1.(currently amended) A pharmaceutical composition for treating osteoporosis comprising consisting essentially of at least one zwitterionic phospholipid and at least one bisphosphonate.

2.(original) The composition of claim 1, wherein the zwitterionic phospholipid is present in an amount sufficient to reduce GI toxicity of the bisphosphonate and the bisphosphonate is present in an amount sufficient to reduce bone resorption.

3.(original) The composition of claim 1, wherein the zwitterionic phospholipid is present in an amount sufficient to reduce GI toxicity of the bisphosphonate and improve bisphosphonate bio-availability when the composition is taken with food and the bisphosphonate is present in an amount sufficient to reduce bone resorption, increase in bone density and/or reduce bone fractures.

4.(original) The composition of claim 3, wherein the amount of bisphosphonate is between about 0.1 mg per dose and about 1000 mg per dose and a ratio of bisphosphonate to zwitterionic phospholipid is between about 1:0.1 and about 1:100.

5.(original) The composition of claim 3, wherein the amount of bisphosphonate is between about 1 mg per dose and about 500 mg per dose and a ratio of bisphosphonate to zwitterionic